Last updated on November 2019

Alternative Schedule Study For VLA15 a Vaccine Candidate Against Lyme Borreliosis


Brief description of study

A total of 250 subjects will be randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (two different dose levels) or Placebo. Vaccinations will be administered as intramuscular injections on Day 1, Day 57 and Day 180.

Study duration per subject will be a maximum of 19 months. Overall study Duration is estimated to be 21 months.

Detailed Study Description

This is a randomized, observer-blind (subject, Sponsor and investigator/site staff involved in Clinical Evaluation of subjects are blinded), Placebo controlled, multicenter Phase 2 study.

A total of 250 healthy subjects,aged 18 to 65 years, will be randomized 2:2:1 to receive either VLA15 with Alum (two different dose levels) or Placebo. Vaccinations will be administered as intramuscular injections on Day 1 (Month 0), Day 57 (Month 2) and Day 180 (Month 6).

Clinical Study Identifier: NCT03970733

Find a site near you

Start Over

Clinical Research Consulting, LLC

Milford, CT United States
0.54miles
  Connect »